Cushings Syndrome and Acromegaly Treatment Market

Introduction

Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing's syndrome cases are caused by pituitary adenoma, and multiple endocrine neoplasia.

Acromegaly involves symptoms such as enlargement of the hands, feet, forehead, jaw, nose etc. resulting in joint pain, thickening of skin, deepening of the voice, headaches, and vision problems. Other complications include type 2 diabetes, and hypertension. Acromegaly is also caused by production of excess growth hormone (GH). Most cases of Acromegaly is due to the pituitary gland producing excessive growth hormone mostly due a benign tumor, known as a pituitary adenoma. The incidence rate of Acromegaly is about 2 to 3 people per million each year.

The Cushing’s Syndrome and Acromegaly treatment market by drug type is segmented into Cushing’s syndrome treatment and Acromegaly treatment. The Cushing’s syndrome treatment is further sub segmented into Glucocorticoid Receptor Inhibitors, Somatostatin, Ketoconazole HRA, and other Off-label.

The Acromegaly treatment is further sub segmented into Somatostatin, Glucocorticoid Receptor Inhibitors, and other Off-label. Based on the distribution channels, the global Cushing’s syndrome and Acromegaly treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Global Cushing’s Syndrome and Acromegaly treatment market:Overview

In terms of revenue, the global Cushing’s Syndrome and Acromegaly treatment market is projected to expand at a CAGR of 9.3% during the forecast period. Asia Pacific is expected to witness siginificant growth in the global Cushing’s Syndrome and Acromegaly treatment market, dominated by Japan, Australia and China.

The global Cushing’s Syndrome and Acromegaly treatment market is segmented into seven major regions, namely North America, Europe, Latin america, Asia Pacific and rest of world. In terms of value, North America is expected to be the dominant regional market for Cushing’s Syndrome and Acromegaly treatment by 2026 and is expected to expand at a CAGR of 9.7% over the forecast period.

Europe and Asia Pacific are expected to be the fast-growing markets in terms of revenue in the global Cushing’s Syndrome and Acromegaly treatment market, registering CAGRs of 8.9% and 10.5%, respectively, over the forecast period. The rest of the world Cushing’s Syndrome and Acromegaly Treatment market is dominated by South Africa and gulf countries owing to their high healthcare expenditure and per capita income.

Technology gains is the large market opportunity for ther Cushing’s Syndrome and Acromegaly treatment market. The development of targeted drug therapy with minimal side effects is expected to drive the adoption of Cushing’s Syndrome and Acromegaly treatment products. The support to orphan diseases and imaging by the governments of different countries is the other factors expected to boost the growth of the market for Cushing’s Syndrome and Acromegaly treatment.

Demographic drivers include the ageing of the world population and the growing healthcare expenditure around the world. The relapse rates for Cushing’s Syndrome and Acromegaly after surgery is as high as 15 to 20 % which is another driver of the Cushing’s Syndrome and Acromegaly treatment market.

Key Region

In North America, the U.S. is the dominant market for Cushing’s Syndrome and Acromegaly treatment due to faster uptake of technology and large purchasing power. The excellent reimbursement and growing incidence of Cushing’s Syndrome and Acromegaly are also expected to support the growth of the market for Cushing’s Syndrome and Acromegaly treatment. Besides, presence of large players such as Novartis AG, Pfizer Inc. and others is also expected to drive the growth of the Cushing’s Syndrome and Acromegaly treatment market in the U.S. The healthcare expenditure in the U.S. was almost 16% of its GDP in 2017, which amply reflects better pricing and market attractiveness.

The second dominant market for Cushing’s Syndrome and Acromegaly treatment is Europe which is dominated by Germany owing to the presence of large medical industry and presence of advanced players, such as HRA Pharma. The growing healthcare infrastructure as well as healthcare expenditure of Europe, which accounts to average 10 % of the GDP, are factors driving the growth of the Europe Cushing’s Syndrome and Acromegaly treatment market. Other European nations with a sizeable market are France, the U.K. and Spain.

Key Player

The Asia Pacific market is dominated by Japan, Australia and India. However, China is expected to witness fast growth in the Asia Pacific Cushing’s Syndrome and Acromegaly Treatment market. The consolidation of large healthcare providers coupled with greater healthcare insurance penetration is another driver of the Cushing’s Syndrome and Acromegaly treatment market.

Market Segmentation

Attribute	Details
Hrug types	Cushing’s Syndrome Treatment Glucocorticoid Receptor Inhibitors Somatostatin Ketoconazole HRA Other Off-label Acromegaly Treatment Somatostatin Glucocorticoid Receptor Inhibitors Other Off-label
Distribution channels	Hospital Pharmacies Retail Pharmacies Online Pharmacies
Basis of regions	North America U.S. Canada Western Europe Germany France U.K. Russia Spain Rest of Western Europe Latin America Brazil Mexico Rest of Latin America Asia Pacific Australia China Japan India Rest of Asia Pacific Rest of World GCC Countries South Africa Rest of World

To know more about delivery timeline for this report Contact Sales